Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021
Open accessAbstract
This JAMA Insights review provides clinical details of anaphylactic reactions reported to and verified by the CDC in the first month of use of the Pfizer-BioNTech and Moderna COVID-19 vaccines in the US, December 14, 2020-January 18, 2021.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Anaphylactic reactions have been observed in approximately 2.5 per million anti-COVID-19 vaccinations with the Moderna vaccine.
“Anaphylactic reactions have been observed in approximately 4.7 per million anti-COVID-19 vaccinations with the Pfizer–BioNTech vaccine and 2.5 per million vaccinations with the Moderna vaccine213”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [213]
Anaphylactic reactions have been observed in approximately 4.7 per million anti-COVID-19 vaccinations with the Pfizer-BioNTech vaccine.
“Anaphylactic reactions have been observed in approximately 4.7 per million anti-COVID-19 vaccinations with the Pfizer–BioNTech vaccine and 2.5 per million vaccinations with the Moderna vaccine213”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [213]
Rare events of anaphylaxis have been reported after vaccination with mRNA-1273 and BNT162b2, with an incidence currently estimated at approximately 1 in 100,000.
“Rare events of anaphylaxis have been reported after vaccination with mRNA-1273 and BNT162b2, with an incidence currently estimated at approximately 1 in 100,000 [86].”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [86]
Most confirmed anaphylaxis cases after mRNA vaccination had a documented history of allergic reactions and/or anaphylaxis.
“Of the confirmed cases, most of the individuals had a documented history of allergic reactions and/or anaphylaxis.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [86]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)
Shimabukuro, T. T., Nguyen, M., Martin, D., & Destefano, F. R. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.07.035 · Cited by 609 · see citing works
Self-citationOliver, S. E., Gargano, J. W., Marin, M., Wallace, M. M., Curran, K. G., Chamberland, M. E., McClung, N. M., Campos-Outcalt, D. E., Morgan, R. L., Mbaeyi, S. A., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6950e2 · Cited by 536 · see citing works
Rüggeberg, J. U., Gold, M., Bayas, J. M., Blum, M. D., Bonhoeffer, J., Friedlander, S. F., Brito, G. D. S., Heininger, U., Imoukhuede, E. B., Khamesipour, A., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.02.064 · Cited by 383 · see citing works
Rossen, L. M., Branum, A. M., Ahmad, F. B., Sutton, P., & Anderson, R. N. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6942e2 · Cited by 373 · see citing works
Shimabukuro, T. T., & Nair, N. (2021) · JAMA · doi:10.1001/jama.2021.0600 · Cited by 327 · see citing works
Self-citationOliver, S. E., Gargano, J. W., Marin, M., Wallace, M. M., Curran, K. G., Chamberland, M. E., McClung, N. M., Campos-Outcalt, D. E., Morgan, R. L., Mbaeyi, S. A., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm695152e1 · Cited by 317 · see citing works
Vaccine-associated hypersensitivity
McNeil, M. M., & Destefano, F. R. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.12.971 · Cited by 274 · see citing works
CDC COVID-19 Response Team, & Administration, F. A. D. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7004e1 · Cited by 270 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555 · see citing works
Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z., & Pierce, B. F. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00592-1 · Cited by 1,110 · see citing works
McMahon, D. E., Amerson, E. H., Rosenbach, M. A., Lipoff, J. B., Moustafa, D., Tyagi, A., Desai, S. R., French, L. E., Lim, H. W., THIERS, B. H., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.03.092 · Cited by 808 · see citing works
Surveillance for Adverse Events After COVID-19 mRNA Vaccination
Klein, N. P., Lewis, N., Goddard, K., FIREMAN, B. H., Zerbo, O., Hanson, K. E., Donahue, J. G., Kharbanda, E. O., Naleway, A. L., Nelson, J. C., et al. (2021) · JAMA · doi:10.1001/jama.2021.15072 · Cited by 623 · see citing works
Self-citationUnlocking the promise of mRNA therapeutics
Rohner, E., Yang, R., Foo, K. S., Goedel, A., & Chien, K. R. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01491-z · Cited by 612 · see citing works
Shi, D., Beasock, D., Fessler, A., Szebeni, J., Ljubimova, J. Y., Afonin, K. A., & Dobrovolskaia, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114079 · Cited by 535 · see citing works
The landscape of mRNA nanomedicine
Huang, X., Kong, N., Zhang, X., Cao, Y., Langer, R., & Tao, W. (2022) · Nature Medicine · doi:10.1038/s41591-022-02061-1 · Cited by 511 · see citing works
The dawn of mRNA vaccines: the COVID-19 case
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.043 · Cited by 504 · see citing works
Ibrahim, M. Y., Ramadan, E., Elsadek, N. E., Emam, S. E., Shimizu, T., Ando, H., Ishima, Y., El-Garhy, O. H., Sarhan, H. A., Hussein, A. K., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.031 · Cited by 481 · see citing works
A Comprehensive Review of mRNA Vaccines
Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S., & Khan, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032700 · Cited by 457 · see citing works
Gee, J., Marquez, P., Su, J., Calvert, G. M., Liu, R., Myers, T., Nair, N., Martin, S., Clark, T., Markowitz, L., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7008e3 · Cited by 395 · see citing works
Self-citationBorobia, A. M., Carcas, A. J., Pérez‐Olmeda, M., Castaño, L. A., Bertran, M. J., García‐Pérez, J., Campins, M., Portolés, A., González-Pérez, M., Morales, M. T. G., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01420-3 · Cited by 350 · see citing works
Suzuki, Y., & Ishihara, H. (2021) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2021.100424 · Cited by 304 · see citing works
Acute Allergic Reactions to mRNA COVID-19 Vaccines
Blumenthal, K. G., Robinson, L. B., Camargo, C. A., Shenoy, E. S., Banerji, A., Landman, A., & Wickner, P. G. (2021) · JAMA · doi:10.1001/jama.2021.3976 · Cited by 274 · see citing works
mRNA Vaccines in the COVID-19 Pandemic and Beyond
Hogan, M. J., & Pardi, N. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042420-112725 · Cited by 252 · see citing works
Evaluation of the safety profile of COVID-19 vaccines: a rapid review
Wu, Q., Dudley, M. Z., Chen, X., Bai, X., Dong, K., Zhuang, T., Salmon, D. A., & Yu, H. (2021) · BMC Medicine · doi:10.1186/s12916-021-02059-5 · Cited by 241 · see citing works
Català, A., Muñoz‐Santos, C., Galván‐Casas, C., Riesco, M. R., Revilla‐Nebreda, D., Truyols, A. S., Giavedoni, P., Llamas‐Velasco, M., González‐Cruz, C., Cubiró, X., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20639 · Cited by 239 · see citing works
Greenhawt, M., Abrams, E. M., Shaker, M. S., Chu, D. K., Khan, D. A., Akin, C., Alqurashi, W., Arkwright, P. D., Baldwin, J. L., Ben‐Shoshan, M., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.06.006 · Cited by 204 · see citing works
ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine
Shakoor, M. T., Birkenbach, M. P., & Lynch, M. R. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.06.016 · Cited by 189 · see citing works
Rosenblum, H. G., Gee, J. M., Liu, R., Marquez, P. L., Zhang, B., Strid, P., Abara, W. E., McNeil, M. M., Myers, T. R., Hause, A. M., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00054-8 · Cited by 176 · see citing works
Self-citationRecent Advancement in mRNA Vaccine Development and Applications
Fayez, N. A., Nassar, M. S., Alshehri, A. A., Alnefaie, M. K., Almughem, F. A., Alshehri, B. Y., Alawad, A. O., & Tawfik, E. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071972 · Cited by 177 · see citing works
Menstrual Symptoms After COVID-19 Vaccine: A Cross-Sectional Investigation in the MENA Region
Muhaidat, N., Alshrouf, M. A., Azzam, M., Karam, A. M., Al-Nazer, M., & Al-Ani, A. (2022) · International Journal of Women s Health · doi:10.2147/ijwh.s352167 · Cited by 167 · see citing works
Targeted modulation of immune cells and tissues using engineered biomaterials
Yousefpour, P., Ni, K., & Irvine, D. J. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-022-00016-2 · Cited by 169 · see citing works
Scholkmann, F., & May, C.-A. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154497 · Cited by 156 · see citing works
First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing
Wolfson, A. R., Robinson, L. B., Li, L., McMahon, A. E., Cogan, A. S., Fu, X., Wickner, P. G., Samarakoon, U., Saff, R. R., Blumenthal, K. G., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.06.010 · Cited by 140 · see citing works
Lack of consideration of sex and gender in COVID-19 clinical studies
Brady, E., Nielsen, M. W., Andersen, J. P., & Oertelt‐Prigione, S. (2021) · Nature Communications · doi:10.1038/s41467-021-24265-8 · Cited by 139 · see citing works
Luxi, N., Giovanazzi, A., Capuano, A., Crisafulli, S., Cutroneo, P. M., Fantini, M. P., Ferrajolo, C., Moretti, U., Poluzzi, E., Raschi, E., et al. (2021) · Drug Safety · doi:10.1007/s40264-021-01131-6 · Cited by 137 · see citing works
Warren, C. M., Snow, T. T., Lee, A., Shah, M. M., Heider, A., Blomkalns, A. L., Betts, B. A., Buzzanco, A. S., González, J. C., Chinthrajah, R. S., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.25524 · Cited by 132 · see citing works
Hartwell, B., Melo, M., Xiao, P., Lemnios, A. A., Li, N., Chang, J. Y. H., Yu, J.-Y., Gebre, M. S., Chang, A., Maiorino, L., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn1413 · Cited by 108 · see citing works
Focus on Sex and Gender: What We Need to Know in the Management of Rheumatoid Arthritis
Maranini, B., Bortoluzzi, A., Silvagni, E., & Govoni, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030499 · Cited by 111 · see citing works
From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape
Chakraborty, C., Sharma, A. R., Bhattacharya, M., & Lee, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679344 · Cited by 111 · see citing works
Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine
Green, M. S., Peer, V., Magid, A., HaGani, N., Anis, E., & Nitzan, D. (2022) · Vaccines · doi:10.3390/vaccines10020233 · Cited by 106 · see citing works
Current Developments and Challenges of mRNA Vaccines
Chen, J., Chen, J., & Xu, Q. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110220-031722 · Cited by 106 · see citing works
Kim, M., Lee, Y. W., Kim, S. R., Kim, J., Min, T. K., Park, H., Shin, M., Ye, Y., Lee, S., Lee, J., et al. (2021) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2021.13.4.526 · Cited by 92 · see citing works
COVID-19 vaccines: Considering sex differences in efficacy and safety
Jensen, A., Strømme, M., Moyassari, S., Chadha, A. S., Tartaglia, M. C., Szoeke, C. E. I., & Ferretti, M. T. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106700 · Cited by 89 · see citing works
Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis
Mateja, A., Wang, Q., Chovanec, J., Kim, J., Wilson, K. J., Schwartz, L. B., Glover, S. C., Carter, M. C., Metcalfe, D. D., Brittain, E., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.08.007 · Cited by 91 · see citing works
The role and impact of polyethylene glycol on anaphylactic reactions to COVID-19 nano-vaccines
Bigini, P., Gobbi, M., Bonati, M. R., Clavenna, A., Zucchetti, M., Garattini, S. K., & Pasut, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-01001-3 · Cited by 86 · see citing works
Ocular adverse events following vaccination: overview and update
Cheng, J. Y., & Margo, C. E. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2021.04.001 · Cited by 79 · see citing works
Incidence of Cutaneous Reactions After Messenger RNA COVID-19 Vaccines
Robinson, L. B., Fu, X., Hashimoto, D. M., Wickner, P. G., Shenoy, E. S., Landman, A., & Blumenthal, K. G. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.2114 · Cited by 79 · see citing works
COVID-19 mRNA Vaccine and Myocarditis
Singh, B., Kaur, P., Cedeno, L., Brahimi, T., Patel, P., Virk, H., Shamoon, F. E., & Bikkina, M. (2021) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2021_002681 · Cited by 78 · see citing works
Sex and Gender in COVID-19 Vaccine Research: Substantial Evidence Gaps Remain
Vassallo, A. J., Shajahan, S., Harris, K., Hallam, L., Hockham, C., Womersley, K., Woodward, M., & Sheel, M. (2021) · Frontiers in Global Women s Health · doi:10.3389/fgwh.2021.761511 · Cited by 78 · see citing works
The impact of information sources on COVID-19 vaccine hesitancy and resistance in sub-Saharan Africa
Osuagwu, U. L., Mashige, K. P., Ovenseri-Ogbomo, G. O., Envuladu, E. A., Abu, E. K., Miner, C. A., Timothy, C. G., Ekpenyong, B. N., Langsi, R., Amiebenomo, O. M.-A., et al. (2023) · BMC Public Health · doi:10.1186/s12889-022-14972-2 · Cited by 74 · see citing works
mRNA vaccines: The future of prevention of viral infections?
Rzymski, P., Szuster‐Ciesielska, A., Dzieciątkowski, T., Gwenzi, W., & Fal, A. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28572 · Cited by 74 · see citing works
Six months of COVID vaccines: what 1.7 billion doses have taught scientists
Ledford, H. K. (2021) · Nature · doi:10.1038/d41586-021-01505-x · Cited by 67 · see citing works
COVID ‐19: vaccination problems
Brüssow, H. (2021) · Environmental Microbiology · doi:10.1111/1462-2920.15549 · Cited by 66 · see citing works
McMurry, R., Lenehan, P. J., Awasthi, S., Silvert, E., Puranik, A., Pawlowski, C., Venkatakrishnan, A., Anand, P., Agarwal, V., O’Horo, J. C., et al. (2021) · Med · doi:10.1016/j.medj.2021.06.006 · Cited by 65 · see citing works
Anaphylaxis to the first dose of mRNA SARS‐CoV‐2 vaccines: Don't give up on the second dose!
Krantz, M. S., Bruusgaard‐Mouritsen, M. A., Koo, G., Phillips, E. J., Stone, C. A., & Garvey, L. H. (2021) · Allergy · doi:10.1111/all.14958 · Cited by 65 · see citing works
Brief review of the mRNA vaccines COVID-19
Vitiello, A., & Ferrara, F. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00811-0 · Cited by 64 · see citing works
Anaphylaxis: Revision of the Brighton collaboration case definition
Gold, M., Amarasinghe, A., Greenhawt, M., Kelso, J. M., Kochhar, S., Thong, B. Y., Top, K. A., Turner, P., Worm, M., & LAW, B. J. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.11.027 · Cited by 61 · see citing works
COVAX-19Ⓡ Vaccine: Completely blocks virus transmission to non-immune individuals
Chavda, V. P., Vora, L. K., & Vihol, D. R. (2021) · Clinical Complementary Medicine and Pharmacology · doi:10.1016/j.ccmp.2021.100004 · Cited by 60 · see citing works
Tailoring the physicochemical properties of nanomaterials for immunomodulation
Deng, J., Wang, J., Shi, J., Li, H., Lu, M., Fan, Z., Gu, Z., & Cheng, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114039 · Cited by 60 · see citing works
Yang, W., Wang, L., Fang, M., Sheth, V. M., Zhang, Y., Holden, A., Donahue, N. D., Green, D. E., Frickenstein, A. N., Mettenbrink, E. M., et al. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c00349 · Cited by 56 · see citing works
Messenger RNA vaccines for cancer immunotherapy: progress promotes promise
Huff, A. L., Jaffee, E. M., & Zaidi, N. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156211 · Cited by 56 · see citing works
Nano-bio interactions in mRNA nanomedicine: Challenges and opportunities for targeted mRNA delivery
Saiding, Q., Zhang, Z., Chen, S., Xiao, F., Chen, Y., Li, Y., Zhen, X., Khan, M. M., Chen, W., Koo, S., et al. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115116 · Cited by 57 · see citing works
Gaballa, S. A., Shimizu, T., Ando, H., Takata, H., Emam, S. E., Ramadan, E., Naguib, Y. W., Mady, F. M., Khaled, K. A., & Ishida, T. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.11.001 · Cited by 59 · see citing works
Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study
Hatziantoniou, S., Maltezou, H. C., Tsakris, A., Poland, G. A., & Anastassopoulou, C. G. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.073 · Cited by 53 · see citing works
Vaccine hesitancy: the greatest threat to COVID-19 vaccination programs
Nossier, S. A. (2021) · Journal of the Egyptian Public Health Association · doi:10.1186/s42506-021-00081-2 · Cited by 55 · see citing works
Seirafianpour, F., Pourriyahi, H., Mesgarha, M. G., Mohammad, A. P., Shaka, Z., & Goodarzi, A. (2022) · Dermatologic Therapy · doi:10.1111/dth.15461 · Cited by 49 · see citing works
Pitlick, M. M., Sitek, A. N., Kinate, S., Joshi, A. Y., & Park, M. A. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.03.012 · Cited by 48 · see citing works
Vaccine allergy: evidence to consider for COVID-19 vaccines
Nilsson, L. E., Csuth, Á., Storsæter, J., Garvey, L. H., & Jenmalm, M. C. (2021) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000762 · Cited by 48 · see citing works
Xu, K., Dai, L., & Gao, G. F. (2021) · International Immunology · doi:10.1093/intimm/dxab061 · Cited by 48 · see citing works
Pfizer-BioNTech COVID-19 Vaccine Tolerance in Allergic versus Non-Allergic Individuals
Nittner‐Marszalska, M., Rosiek‐Biegus, M., Kopeć, A., Pawłowicz, R., Kosińska, M., Łata, A., & Szenborn, L. (2021) · Vaccines · doi:10.3390/vaccines9060553 · Cited by 47 · see citing works
Parents’ hesitation about getting their children vaccinated against COVID-19 in Japan
Yoda, T., & Katsuyama, H. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1981087 · Cited by 47 · see citing works
COVID-19 and the Endocrine System: A Review of the Current Information and Misinformation
Mirza, S. A., Sheikh, A. A. E., Barbera, M., Ijaz, Z., Javaid, M. A., Shekhar, R., Pal, S., & Sheikh, A. B. (2022) · Infectious Disease Reports · doi:10.3390/idr14020023 · Cited by 50 · see citing works
Shiloh, S., Peleg, S., & Nudelman, G. (2021) · Annals of Behavioral Medicine · doi:10.1093/abm/kaab101 · Cited by 47 · see citing works
Banerji, A., Wolfson, A. R., Wickner, P. G., Cogan, A. S., McMahon, A. E., Saff, R. R., Robinson, L. B., Phillips, E. J., & Blumenthal, K. G. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.03.053 · Cited by 47 · see citing works
Immunity to SARS-CoV-2: Lessons Learned
FERGIE, J. E., & Srivastava, A. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654165 · Cited by 45 · see citing works
Experience with polyethylene glycol allergy‐guided risk management for COVID‐19 vaccine anaphylaxis
Brockow, K., Mathes, S., Fischer, J., Volc, S., Darsow, U. G., Eberlein, B., & Biedermann, T. (2021) · Allergy · doi:10.1111/all.15183 · Cited by 46 · see citing works
Wong, C. K. H., Lau, K. T. K., Xiong, X., Au, I. C. H., Lai, F. T. T., Wan, E. Y. F., Chui, C. S. L., Li, X., Chan, E. W., Gao, L., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1004018 · Cited by 45 · see citing works
Cutaneous manifestations of COVID ‐19 and COVID ‐19 vaccination
Nakashima, C., Kato, M., & Otsuka, A. (2023) · The Journal of Dermatology · doi:10.1111/1346-8138.16651 · Cited by 44 · see citing works
Bonadonna, P., Brockow, K., Niedoszytko, M., Elberink, H. O., Akin, C., Nedoszytko, B., Butterfield, J. H., Álvarez‐Twöse, I., Sotlar, K., Schwaab, J., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.03.041 · Cited by 41 · see citing works
Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond
Weinberger, B. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00249-6 · Cited by 43 · see citing works
Deyhimfar, R., Izady, M., Shoghi, M., Kazazi, M. H., Ghazvini, Z. F., Nazari, H., Fekrirad, Z., & Arefian, E. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26971 · Cited by 40 · see citing works
Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children
Hutton, D. W., Prosser, L. A., Rose, A. M., Mercon, K. R., Ortega‐Sanchez, I. R., Leidner, A. J., McMorrow, M., Fleming-Dutra, K. E., Prill, M. M., Pike, J. J., et al. (2024) · PEDIATRICS · doi:10.1542/peds.2024-066461 · Cited by 43 · see citing works
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management
Luxi, N., Giovanazzi, A., Arcolacı, A., Bonadonna, P., Crivellaro, M., Cutroneo, P. M., Ferrajolo, C., Furci, F., Guidolin, L., Moretti, U., et al. (2022) · BioDrugs · doi:10.1007/s40259-022-00536-8 · Cited by 37 · see citing works
Sex differences in airway disease: estrogen and airway surface liquid dynamics
Harvey, B. J., & McElvaney, N. G. (2024) · Biology of Sex Differences · doi:10.1186/s13293-024-00633-z · Cited by 38 · see citing works
Hodel, K. V. S., Fiuza, B. S. D., Conceição, R. S., Aleluia, A. C. M., Pitanga, T. N., Fonseca, L. M. D. S., Valente, C. O., Rezende, C. S. M. E., & Machado, B. A. S. (2024) · Pharmaceuticals · doi:10.3390/ph17060807 · Cited by 38 · see citing works
Safety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review.
SeyedAlinaghi, S., Karimi, A., Pashaei, Z., Afzalian, A., Mirzapour, P., Ghorbanzadeh, K., Ghasemzadeh, A., Dashti, M., Nazarian, N., Vahedi, F., et al. (2022) · Archives of Academic Emergency Medicine · doi:10.22037/aaem.v10i1.1597 · Cited by 33 · see citing works
Desai, A. P., Desai, A. P., & Loomis, G. J. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.058 · Cited by 34 · see citing works
Iguchi, T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D. (2021) · Drug Safety · doi:10.1007/s40264-021-01104-9 · Cited by 33 · see citing works
ISIDOG Consensus Guidelines on COVID-19 Vaccination for Women before, during and after Pregnancy
Donders, G. G. G., Grincevičienė, Š., Haldre, K., Hoffmann, R., Donders, F., Tsiakalos, A., Adriaanse, A. H., de Oliveira, J. M., Ault, K. A., Mendling, W., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132902 · Cited by 35 · see citing works
Li, L., Robinson, L. B., Patel, R. K., Landman, A., Fu, X., Shenoy, E. S., Hashimoto, D. M., Banerji, A., Wickner, P. G., Samarakoon, U., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.31034 · Cited by 33 · see citing works
Features of Inflammatory Heart Reactions Following mRNA COVID‐19 Vaccination at a Global Level
Chouchana, L., Blet, A., Al-Khalaf, M. H., Kafil, T. S., Nair, G. M., Robblee, J. A., Drici, M., Valnet‐Rabier, M., Micallef, J., Salvo, F., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2499 · Cited by 33 · see citing works
Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines
Somiya, M., Mine, S., Yasukawa, K., & Ikeda, S. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.04.066 · Cited by 32 · see citing works
Deng, L., Glover, C., Dymock, M., Pillsbury, A., Marsh, J. A., Quinn, H., Leeb, A., Cashman, P. M., Snelling, T., Wood, N., et al. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51619 · Cited by 32 · see citing works
mRNA COVID-19 Vaccines—Facts and Hypotheses on Fragmentation and Encapsulation
Jacques Demongeot, A., & Fougère, C. (2022) · Vaccines · doi:10.3390/vaccines11010040 · Cited by 35 · see citing works
Weber, D. J., Al‐Tawfiq, J. A., Babcock, H. M., Bryant, K. A., Drees, M. L., Elshaboury, R. H., Essick, K., Fakih, M. G., Henderson, D. K., Javaid, W., et al. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.322 · Cited by 32 · see citing works
The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis
Sobczak, M., & Pawliczak, R. (2022) · Clinical and Molecular Allergy · doi:10.1186/s12948-022-00167-y · Cited by 31 · see citing works
Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination
Zhou, Z., Cortese, M. M., Fang, J., Wood, R. A., Hummell, D. S., Risma, K., Norton, A. E., KuKuruga, M. A., Kirshner, S., Rabin, R. L., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.029 · Cited by 31 · see citing works
Self-citationPourani, M. R., Shahidi‐Dadras, M., Salari, M., Diab, R., Namazi, N., & Abdollahimajd, F. (2021) · Dermatologic Therapy · doi:10.1111/dth.15223 · Cited by 30 · see citing works
Lee, D. S., Kim, J. W., Lee, K. L., Jung, Y. J., & Kang, H. W. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.03.007 · Cited by 30 · see citing works
Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19)
Baghban, R., Ghasemian, A., & Mahmoodi, S. (2023) · Archives of Microbiology · doi:10.1007/s00203-023-03480-5 · Cited by 33 · see citing works
Vacunas frente a SARS-CoV-2 y piel
Galván‐Casas, C., Català, A., & Muñoz‐Santos, C. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2021.05.011 · Cited by 29 · see citing works
Best Practices for COVID-19 Mass Vaccination Clinics
Shakory, S., Eissa, A., Kiran, T., & Pinto, A. D. (2022) · The Annals of Family Medicine · doi:10.1370/afm.2773 · Cited by 29 · see citing works
Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review
Wollina, U., Chiriac, A. E., Kocić, H., Koch, A., & Brzeziński, P. (2021) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-021-00876-0 · Cited by 28 · see citing works
Brown, K. A., Stall, N. M., Vanniyasingam, T., Buchan, S. A., Daneman, N., Hillmer, M. P., Hopkins, J. P., Johnstone, J., Maltsev, A., McGeer, A., et al. (2021) · doi:10.47326/ocsat.2021.02.13.1.0 · Cited by 28 · see citing works
The conundrum of COVID-19 mRNA vaccine–induced anaphylaxis
Khalid, M. B., & Frischmeyer‐Guerrerio, P. A. (2022) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2022.10.003 · Cited by 27 · see citing works
mRNA COVID-19 Vaccine Anaphylaxis: Epidemiology, Risk Factors, and Evaluation
Jaggers, J. L., & Wolfson, A. R. (2023) · Current Allergy and Asthma Reports · doi:10.1007/s11882-023-01065-2 · Cited by 27 · see citing works
A review of the safety and efficacy of current COVID-19 vaccines
Huang, Z., Su, Y., Zhang, T., & Xia, N. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0893-y · Cited by 27 · see citing works
Nasreen, S., Calzavara, A. J., Buchan, S. A., Thampi, N., Johnson, C., Wilson, S. E., & Kwong, J. C. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.065 · Cited by 26 · see citing works
- Authors
- Shimabukuro, T. T., Cole, M., & Su, J. R.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2021-03-16
- Volume
- 325
- Issue
- 11
- Pages
- 1101
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC8890485
- OpenAlex
- W3128551684
- Cited by
- 475
- References
- 8
- Citations by year
- 2026: 22 · 2025: 27 · 2024: 30 · 2023: 104 · 2022: 136 · 2021: 156
- FWCI
- 33.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (CC999999)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Keywords
- anaphylaxis, COVID-19 mRNA vaccine, BNT162b2, Moderna vaccine, vaccine adverse events, vaccine safety
- MeSH terms
- COVID-19 Vaccines, Adult, Anaphylaxis, Female, Hospitalization, Humans, Male, Middle Aged, United States, Adverse Drug Reaction Reporting Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
